Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
申请人:Dana-Farber Cancer Institute, Inc.
公开号:US10925967B2
公开(公告)日:2021-02-23
The present application provides bifunctional compounds of Formula (X):
or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.
本申请提供了式 (X) 的双官能团化合物:
或其对映体、非对映体或立体异构体,或其药学上可接受的盐、水合物、溶液或原药,它们可作为布鲁顿酪氨酸激酶(BTK)的蛋白质降解诱导分子。本申请还涉及通过使用将泛素连接酶结合分子与能够与 BTK 结合的配体连接起来的双功能化合物靶向降解 BTK 的方法,该方法可用于治疗受 BTK 调节的疾病。